Abiomed Investor Relations Material
Latest events
Q1 2023
Abiomed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Abiomed Inc
Access all reports
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It provides Impella 2.5 system, a percutaneous micro heart pump with integrated motor and sensors for use by interventional cardiologists to treat patients in cardiogenic shock; Impella CP system which enables physicians to treat patients needing circulatory support; Impella 5.0 system that provides left ventricular support; and Impella LD heart pump for use in high risk percutaneous coronary interventions.
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
ABMD
Country
🇺🇸 United States